INTRACELLULAR TRAFFICKING OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REV PROTEIN - INVOLVEMENT OF CONTINUED RIBOSOMAL-RNA SYNTHESIS IN NUCLEAR RETENTION
Dm. Dagostino et al., INTRACELLULAR TRAFFICKING OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REV PROTEIN - INVOLVEMENT OF CONTINUED RIBOSOMAL-RNA SYNTHESIS IN NUCLEAR RETENTION, AIDS research and human retroviruses, 11(9), 1995, pp. 1063-1071
We have explored the mechanism directing the intracellular trafficking
and nucleolar accumulation of the human immunodeficiency virus type 1
(HIV-1) Rev protein, Treatment of Rev-expressing cells with mycopheno
lic acid, an inhibitor of inosine monophosphate dehydrogenase, resulte
d in a redistribution of Rev from the nucleoli to the nucleoplasm and
cytoplasm, In contrast, a Rev effector domain mutant was retained in t
he nucleus, indicating the involvement of this domain in the protein's
nuclear retention/nucleocytoplasmic transport, Identical results were
obtained by inhibiting transcription using actinomycin D or 5,6-dichl
orobenzimidazole riboside, All three drugs were found to inhibit biosy
nthetic labeling of ribosomal RNA and to disrupt nucleolar morphology,
suggesting a correlation between nucleolar/nuclear retention of Rev,
continued ribosomal RNA synthesis, and intact nucleolar architecture,
Results of binding/immunofluorescence assays using isolated, permeabil
ized nuclei and extracts of cells expressing Rev demonstrated that the
protein is able to bind to nucleoli in vitro, in the absence of activ
e cellular processes or eukaryotic posttranslational modifications, Re
v derived from actinomycin D-treated cells showed equivalent binding,
indicating that the inhibitor did not directly interfere with the abil
ity of the protein to interact with nucleolar structures, Rev's intera
ction with nucleoli was directed by the protein's arginine-rich RNA-bi
nding/nucleolar localization domain, and was abrogated by pretreatment
of the nuclei with RNaseA, indicating a requirement for RNA, probably
ribosomal RNA.